|
UMPS expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.32810001569106E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.99350000010357E-07 |
| Normal-vs-Stage2 |
1.464680E-03 |
| Normal-vs-Stage3 |
1.4405999948508E-08 |
| Normal-vs-Stage4 |
2.11839989994189E-10 |
| Stage1-vs-Stage2 |
3.665200E-01 |
| Stage1-vs-Stage3 |
1.784560E-01 |
| Stage1-vs-Stage4 |
7.438800E-03 |
| Stage2-vs-Stage3 |
7.923900E-02 |
| Stage2-vs-Stage4 |
3.916500E-03 |
| Stage3-vs-Stage4 |
1.121160E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.11719999917881E-08 |
| Normal-vs-AfricanAmerican |
3.235000E-03 |
| Normal-vs-Asian |
1.431490E-04 |
| Caucasian-vs-AfricanAmerican |
3.994600E-01 |
| Caucasian-vs-Asian |
3.857400E-01 |
| AfricanAmerican-vs-Asian |
8.556400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.12810000008068E-07 |
| Normal-vs-Female |
2.10480000095714E-08 |
| Male-vs-Female |
7.406200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.00270000003011E-06 |
| Normal-vs-Age(41-60Yrs) |
2.28909999844262E-08 |
| Normal-vs-Age(61-80Yrs) |
8.32949999973742E-07 |
| Normal-vs-Age(81-100Yrs) |
1.300280E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.527200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.294800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.500200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.224400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.588800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.960800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.819770E-02 |
| Classical-VS-Follicular |
7.143600E-01 |
| Classical-VS-Other |
1.986820E-01 |
| Classical-VS-Normal |
1.62850000040571E-07 |
| Tall-VS-Follicular |
6.125800E-02 |
| Tall-VS-Other |
9.443400E-01 |
| Tall-VS-Normal |
9.59200000538729E-08 |
| Follicular-VS-Other |
3.548600E-01 |
| Follicular-VS-Normal |
4.32959999999705E-05 |
| Other-VS-Normal |
1.884620E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.10509999998276E-06 |
| Normal-vs-N1 |
5.26290011571007E-10 |
| N0-vs-N1 |
3.598200E-03 |
|
|
